RXi Pharmaceuticals Corporation (NASDAQ: RXII) today announced that new pre-clinical data using proprietary rxRNA compounds was presented at the Keystone ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE